Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Eli Lilly's $3 Billion Investment Bolsters Global Manufacturing Capacity

Eli Lilly's $3 Billion Investment Bolsters Global Manufacturing Capacity

Eli Lilly and Company has announced a significant expansion of its global manufacturing network with a $3 billion investment in a new oral medicines facility in the Netherlands. This move marks a strategic shift in the company's production capabilities and underscores its commitment to meeting growing demand for its innovative therapies.

NoahAI News11/4/2025
Tempero Bio Halts Alcohol Use Disorder Program, Reevaluating Options

Tempero Bio Halts Alcohol Use Disorder Program, Reevaluating Options

Tempero Bio, a California-based biotech company, has suspended its phase 2-stage alcohol use disorder (AUD) program and is currently assessing its strategic options, according to its partner Nxera Pharma. This unexpected development comes just eight months after the launch of a phase 2 study for TMP-301, the company's lead candidate for AUD treatment.

NoahAI News11/4/2025
Hims & Hers in Talks with Novo Nordisk for Wegovy and New Obesity Pill, Expands into Lab Testing and Longevity

Hims & Hers in Talks with Novo Nordisk for Wegovy and New Obesity Pill, Expands into Lab Testing and Longevity

Hims & Hers Health, Inc., a leading telehealth platform, has announced it is in active discussions with Novo Nordisk to offer Wegovy injections and a forthcoming oral obesity drug through its online platform. This potential partnership comes as Hims & Hers continues to expand its weight loss business and explores new avenues in personalized healthcare.

NoahAI News11/4/2025
Alvotech's Simponi Biosimilar Faces FDA Setback, Delaying Market Entry

Alvotech's Simponi Biosimilar Faces FDA Setback, Delaying Market Entry

Alvotech, an Icelandic biosimilar specialist, has encountered another regulatory hurdle in its quest to bring more affordable alternatives to popular biologic drugs to the U.S. market. The company recently announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for its biosimilar candidate AVT05, a proposed copycat version of Johnson & Johnson's anti-inflammatory drug Simponi (golimumab).

NoahAI News11/4/2025
New In Vivo Cell Therapy Biotech Emerges with Nobel Laureate Backing and $82M Funding

New In Vivo Cell Therapy Biotech Emerges with Nobel Laureate Backing and $82M Funding

Azalea Therapeutics, a new West Coast biotech company, has entered the competitive in vivo cell therapy space with an impressive $82 million in funding and the support of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. The company aims to revolutionize genome editing with a single-dose approach that could have far-reaching implications for the treatment of various diseases.

NoahAI News11/4/2025
Eli Lilly's $3 Billion Investment Boosts Global Manufacturing Capacity

Eli Lilly's $3 Billion Investment Boosts Global Manufacturing Capacity

Eli Lilly and Company has announced a significant expansion of its global manufacturing capabilities with a $3 billion investment in a new oral medicines manufacturing facility in Katwijk, Netherlands. This move marks a major step in the pharmaceutical giant's ongoing efforts to strengthen its global supply chain and increase production capacity for its innovative treatments.

NoahAI News11/3/2025
Tempero Bio Halts Alcohol Use Disorder Program, Evaluates Options

Tempero Bio Halts Alcohol Use Disorder Program, Evaluates Options

Tempero Bio, a California-based biotechnology company, has suspended its phase 2-stage alcohol use disorder (AUD) program and is currently assessing its options, according to its partner Nxera Pharma. This unexpected development comes just eight months after the launch of a phase 2 study for TMP-301, the company's lead candidate for AUD treatment.

NoahAI News11/3/2025
Roche and Manifold Bio Forge $2B Partnership to Advance Blood-Brain Barrier Drug Delivery

Roche and Manifold Bio Forge $2B Partnership to Advance Blood-Brain Barrier Drug Delivery

Roche, a global pharmaceutical giant, has entered into a significant partnership with Manifold Bio, a biotech startup, to develop innovative blood-brain barrier (BBB) shuttle technology. The collaboration, which could be worth up to $2 billion, aims to revolutionize the delivery of therapeutics to the brain for treating neurological and neurodegenerative diseases.

NoahAI News11/3/2025
TScan Therapeutics Restructures, Focuses on Blood Cancer Program Amid Solid Tumor Trial Halt

TScan Therapeutics Restructures, Focuses on Blood Cancer Program Amid Solid Tumor Trial Halt

TScan Therapeutics, a biotechnology company specializing in T-cell receptor (TCR) therapies, has announced a significant restructuring of its operations and pipeline focus. The company is laying off 30% of its workforce and halting a phase 1 solid tumor trial to concentrate resources on its hematological malignancies program.

NoahAI News11/3/2025
Roche Partners with Manifold Bio to Develop AI-Driven Brain Drug Delivery Technology

Roche Partners with Manifold Bio to Develop AI-Driven Brain Drug Delivery Technology

Roche, the Swiss pharmaceutical giant, has announced a significant collaboration with Manifold Bio, a Boston-based startup specializing in artificial intelligence (AI)-driven drug discovery. The partnership aims to overcome one of the most persistent challenges in neuroscience: delivering drugs across the blood-brain barrier (BBB).

NoahAI News11/3/2025
Viral Vector Manufacturing: Optimizing Strategies for Cell and Gene Therapy Development

Viral Vector Manufacturing: Optimizing Strategies for Cell and Gene Therapy Development

In a rapidly evolving landscape of cell and gene therapy (CGT), viral vector manufacturing stands at the forefront of innovation. Recent insights from contract development and manufacturing organizations (CDMOs) highlight critical considerations and strategies for optimizing viral vector production, particularly for adeno-associated virus (AAV) and lentivirus platforms.

NoahAI News11/3/2025
Neurocrine Biosciences Strikes $880M Deal with TransThera for NLRP3 Inhibitors

Neurocrine Biosciences Strikes $880M Deal with TransThera for NLRP3 Inhibitors

Neurocrine Biosciences, a San Diego-based pharmaceutical company, has entered into a significant licensing agreement with China's TransThera Sciences for the development and commercialization of preclinical NLRP3 inhibitors. The deal, potentially worth over $880 million, marks a major step in the pursuit of novel treatments for inflammatory conditions.

NoahAI News11/3/2025
«1...464748...67»